These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 8743199)

  • 1. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys.
    Kaku S; Kawasaki T; Hisamichi N; Sakai Y; Taniuchi Y; Inagaki O; Yano S; Suzuki K; Terazaki C; Masuho Y; Satoh N; Takenaka T; Yanagi K; Ohshima N
    Thromb Haemost; 1996 Apr; 75(4):679-84. PubMed ID: 8743199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by combination with a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, in a rhesus monkey model of coronary thrombosis.
    Kawasaki T; Sato K; Suzuki K; Sakai Y; Taniuchi Y; Kaku S; Yano S; Inagaki O; Tomioka K; Masuho Y; Yanagisawa I; Takenaka T
    Thromb Haemost; 1998 Mar; 79(3):663-7. PubMed ID: 9531059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the antiplatelet effect of YM337 and abciximab in rhesus monkeys.
    Suzuki K; Sakai Y; Hisamichi N; Taniuchi Y; Sato K; Terazaki C; Kaku S; Kawasaki T; Yano S; Inagaki O; Masuho Y
    Eur J Pharmacol; 1997 Oct; 336(2-3):169-76. PubMed ID: 9384230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a GPIIb/IIIa antagonist YM337 in a primate model of middle cerebral artery thrombosis.
    Kaku S; Umemura K; Mizuno A; Yano S; Suzuki K; Kawasaki T; Nakashima M
    Eur J Pharmacol; 1998 Mar; 345(2):185-92. PubMed ID: 9600636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ME3277, a GPIIb/IIIa antagonist reduces cerebral infarction without enhancing intracranial hemorrhage in photothrombotic occlusion of rabbit middle cerebral artery.
    Kawano KI; Fujishima K; Ikeda Y; Kondo K; Umemura K
    J Cereb Blood Flow Metab; 2000 Jun; 20(6):988-97. PubMed ID: 10894182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic effect of a humanized anti-GPIIb/IIIa monoclonal antibody, YM207, in a photochemically induced thrombosis model in monkeys.
    Kaku S; Kawasaki T; Sakai Y; Taniuchi Y; Yano S; Suzuki K; Terazaki C; Kawamura K; Masuho Y; Satoh N
    Eur J Pharmacol; 1995 Jun; 279(2-3):115-21. PubMed ID: 7556391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties.
    Suzuki K; Sato K; Kamohara M; Kaku S; Kawasaki T; Yano S; Iizumi Y
    Biol Pharm Bull; 2002 Aug; 25(8):1006-12. PubMed ID: 12186399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antithrombotic effect of aurin tricarboxylic acid in the guinea pig is not solely due to its interaction with the von Willebrand factor-GPIb axis.
    Azzam K; Cissé-Thiam M; Drouet L
    Thromb Haemost; 1996 Jan; 75(1):203-10. PubMed ID: 8713802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet effect of FK633, a platelet glycoprotein IIb/IIIa antagonist, on thrombus formation and vascular patency after thrombolysis in the injured hamster carotid artery.
    Kaida T; Matsuno H; Niwa M; Kozawa O; Miyata H; Uematsu T
    Thromb Haemost; 1997 Mar; 77(3):562-7. PubMed ID: 9066011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamic effects of a new antibody glycoprotein IIb/IIIa inhibitor (YM337) in healthy subjects.
    Harder S; Kirchmaier CM; Krzywanek HJ; Westrup D; Bae JW; Breddin HK
    Circulation; 1999 Sep; 100(11):1175-81. PubMed ID: 10484537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex vivo evaluation of anti-GPVI antibody in cynomolgus monkeys: dissociation between anti-platelet aggregatory effect and bleeding time.
    Matsumoto Y; Takizawa H; Nakama K; Gong X; Yamada Y; Tandon NN; Kambayashi J
    Thromb Haemost; 2006 Aug; 96(2):167-75. PubMed ID: 16894460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative studies on the antiplatelet effects of a humanized anti-platelet glycoprotein IIb/IIIa antibody (YM337) and ReoPro under flow conditions.
    Kuwahara M; Sugimoto M; Tsuji S; Miyata S; Nishio K; Kaku S; Suzuki K; Kawasaki T; Yoshioka A
    Thromb Haemost; 1998 Jul; 80(1):28-31. PubMed ID: 9684780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the antiplatelet agent potential of the whole molecule, F(ab)2 and Fab fragments of humanized anti-GPIIb/IIIa monoclonal antibody in monkeys.
    Kaku S; Yano S; Kawasaki T; Sakai Y; Suzuki K; Kawamura K; Masuho Y; Satoh N; Takenaka T; Landolfi NF; Co MS
    Gen Pharmacol; 1996 Apr; 27(3):435-9. PubMed ID: 8723521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats.
    Li H; Lockyer S; Concepcion A; Gong X; Takizawa H; Guertin M; Matsumoto Y; Kambayashi J; Tandon NN; Liu Y
    Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1199-205. PubMed ID: 17322098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thromboxane A(2) synthase inhibitor enhanced antithrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding.
    Kawano KI; Hokamura K; Kondo K; Ikeda Y; Suzuki Y; Umemura K
    Eur J Pharmacol; 2001 Apr; 417(3):217-22. PubMed ID: 11334853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo.
    Herault JP; Peyrou V; Savi P; Bernat A; Herbert JM
    Thromb Haemost; 1998 Feb; 79(2):383-8. PubMed ID: 9493595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons.
    Fontayne A; Meiring M; Lamprecht S; Roodt J; Demarsin E; Barbeaux P; Deckmyn H
    Thromb Haemost; 2008 Oct; 100(4):670-7. PubMed ID: 18841291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban.
    Umemura K; Kondo K; Ikeda Y; Nakashima M
    Thromb Haemost; 1997 Nov; 78(5):1381-4. PubMed ID: 9408023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.